Digital Pathology Technology Landscape — PatSnap Eureka
Digital Pathology Technology Landscape 2026
AI-driven biomarker inference, whole-slide imaging, and spatial tumor microenvironment analysis are redefining cancer diagnostics. Explore the patent and literature signals shaping this field — from Paige.AI's 12-jurisdiction IP strategy to Genentech's spatial TME dominance.
Four Principal Technical Activities in Digital Pathology
The patent landscape maps to four distinct innovation clusters, from foundational WSI infrastructure through to frontier spatial and AR-based approaches.
Whole-Slide Image (WSI) Analysis Platforms
The foundational workflow involves high-resolution scanning of histology slides stained with hematoxylin and eosin (H&E) or immunohistochemical (IHC) agents, tiling the resulting gigapixel images into patches, and applying deep learning models to classify, segment, or infer biological properties. Ventana Medical Systems (Roche) established the performance benchmark with pre-computation of biomarker expression across entire tissue slides, with results returned in seconds across millions of cells. Koninklijke Philips N.V. extended this with LIS–WSI integration frameworks eliminating specimen identification errors.
Ventana · Philips · RocheAI-Driven Biomarker & Genomic Inference
The largest and most commercially active cluster. Rather than performing separate molecular assays, these systems train deep learning models to infer biomarker status (HER2, ER/PR), genomic panel elements, and actionable mutations directly from H&E or IHC-stained WSIs. The technical mechanism typically involves patch-level classification with a trained CNN or transformer followed by slide-level aggregation. Paige.AI and Roche/Genentech are the dominant assignees, with filings covering prediction of oncogene driver mutations, gene fusions, and treatment resistance directly from tissue images.
Paige.AI · Genentech · RocheSpatial Tumor Microenvironment Analysis
This cluster focuses on quantifying the spatial relationships between different cell populations — notably tumor cells and lymphocytes — within tissue sections to generate immunophenotyping outputs, predict immunotherapy response, and stratify clinical trial eligibility. The mechanism involves detecting cell locations, computing spatial distribution metrics, and mapping these to predicted biological states. Genentech is the dominant assignee in this sub-field, with filings specifically referencing checkpoint inhibitor (anti-PD-L1/PD-1) therapy eligibility as a direct output of spatial feature computation.
Genentech dominant assigneeAugmented Reality Microscopy & Active Learning
This cluster addresses the human-in-the-loop layer — delivering AI inferences to pathologists through augmented reality overlays on physical microscopes or through active learning interfaces that capture pathologist feedback to iteratively improve models. The mechanism integrates image acquisition from the microscope optical path, AI analysis, and AR projection in real time. Google's EP-granted AR microscope projects heatmaps and quantitative biomarker data onto the microscope field of view as slides are repositioned or refocused. Ventana's active learning system uses confidence-metric-driven display with a pathologist feedback loop updating model parameters.
Google · Tencent · VentanaJurisdiction & Assignee Intelligence
Key quantitative signals from the digital pathology patent dataset spanning 2012 to 2026, based on records retrieved via PatSnap.
Patent Filings by Jurisdiction
Japan leads with ~25 filings, predominantly international families from US-headquartered companies entering the Japanese market.
Top Assignees by Filing Volume
Paige.AI and Genentech/Roche together account for the majority of digital pathology patent records in this dataset.
From Oncology to Veterinary Pathology
The dominant application domain across this dataset is oncology. Filings address breast, prostate, lung, colorectal, gastric, pancreatic, cervical, ovarian, endometrial, and bladder cancers. Prognostic prediction from WSIs — mapping image features to survival, recurrence scores, or pathologic response — is the most represented use case. Verily Life Sciences filed in JP (2024) for deep learning ensemble models analyzing tissue patches to directly predict patient survival probability.
Immunotherapy response prediction is a rapidly growing sub-domain linking spatial pathology features to immunotherapy eligibility. Genentech's spatial distribution filings specifically reference checkpoint inhibitor (anti-PD-L1/PD-1) therapy eligibility as a direct output of spatial feature computation. According to WHO and FDA guidance frameworks, computational pathology tools must demonstrate clinical validity before regulatory acceptance as companion diagnostics.
A literature record documents gastrointestinal and endoscopic pathology AI screening of normal large bowel endoscopic biopsies using a graph neural network incorporating pathologist domain knowledge, validated across multiple NHS sites and a Portuguese site (6,591 WSIs from 3,291 patients). Telepathology and veterinary pathology (IDEXX Laboratories, 2024 PCT) represent emerging adjacent application territories with relatively limited prior art.
For life sciences organisations evaluating digital pathology IP, PatSnap's life sciences intelligence platform provides dedicated tools for biomarker and oncology patent landscape analysis.
Emerging Directions in Digital Pathology Innovation
Among the most recent filings in this dataset, five directional signals are evident — ranging from foundation model architectures to multimodal convergence.
Self-Supervised & Foundation Model Architectures
Janssen's 2026 JP filing describes hierarchical encoding using DINOv2 and contrastive learning (simCLR) objectives to pre-train patch-level and region-level encoders — signaling the adoption of vision foundation model techniques adapted for gigapixel pathology images. This approach reduces dependence on expensive labeled annotations.
Tumor Heterogeneity as Molecular Testing Surrogate
Genentech's 2026 JP filing uses patch-level label heterogeneity metrics to predict genetic mutation variability without DNA sequencing — positioning H&E image analysis as a cost-effective front-line molecular screening tool. This directly challenges the molecular diagnostics market if regulators accept these inferences as clinically actionable.
IP Strategy Implications for R&D and Innovation Teams
Key strategic signals derived from the digital pathology patent landscape, relevant for R&D strategy, FTO analysis, and competitive positioning. Teams using PatSnap Analytics can validate these signals against live patent data.
| Strategic Signal | Key Assignees | Implication | Priority |
|---|---|---|---|
| Dominant IP in biomarker inference & spatial TME | Roche/Genentech, Paige.AI | Entrants seeking freedom to operate in these specific areas should conduct thorough FTO analysis before committing R&D resources to overlapping claim spaces. | High |
| Foundation model compression of training data advantage | Janssen, Ibex Medical Analytics, Valar Labs | The shift toward self-supervised architectures will compress the training data advantage currently held by large incumbents. Smaller specialized players may compete on domain-specific fine-tuning. | Medium |
| H&E morphology replacing molecular assays | Genentech, Roche, Paige.AI | Prediction of molecular features directly from H&E morphology — without IHC or sequencing — is becoming a central commercial proposition. R&D teams should monitor FDA and CE-IVD guidance closely. | High |
| Japan as primary international filing destination | All major US-headquartered assignees | Japan is the primary international filing destination for digital pathology IP in this dataset. Companies without JP presence risk exclusion from this market. | Medium |
| Whitespace in veterinary pathology & telepathology networks | IDEXX Laboratories, QTC Management | Veterinary pathology and telepathology network optimization are underserved IP territories relative to their market potential. Both represent whitespace opportunities for platform or infrastructure players. | Opportunity |
Validate These Signals Against Live Patent Data
Run FTO analysis, track competitor filings, and identify whitespace with PatSnap Eureka.
From Foundational Filings to AI-Native Architectures
The earliest relevant filings in this dataset date to 2012, with the University of Medicine and Dentistry of New Jersey (New Jersey Medical School) disclosing an image-based computer-assisted prognosis (CAP) system for predicting survival from digitized histopathology slides. This represents a foundational filing establishing the core proposition: that quantitative image features from tissue slides can replicate the prognostic power of molecular assays.
The 2016–2019 period shows early system-level filings: Ventana Medical Systems' WSI workflow patent (JP, 2019), an automated cervical cancer diagnosis system from Pathtech Co., Ltd. (KR, 2016), and Ibex Medical Analytics' personalization framework (WO, 2020). These represent the transition from digitization infrastructure to clinical decision support.
The 2021–2023 period marks a decisive pivot toward AI-native architectures. Paige.AI filed multi-jurisdictional families across the US, CA, SG, AU, BR, WO, JP, and KR covering digital biomarker delivery and genomic panel inference. Genentech's spatial feature analysis filings accumulated across JP and US jurisdictions. Tencent Technology's augmented reality microscope platform received EP and US grants. According to EPO filing trends, AI-assisted medical imaging is among the fastest-growing patent technology areas globally.
The 2024–2026 period — the most recent and densest cluster in this dataset — signals several frontier directions: self-supervised and attention-based learning architectures from Janssen Research & Development (JP, 2026), heterogeneity assessment from Genentech (JP, 2026), telepathology workflow optimization from QTC Management (US, 2026), and Sony Corporation of America's automated tumor cellularity estimation (JP, 2025). For organisations tracking this space, PatSnap customer case studies demonstrate how R&D teams monitor patent landscapes in real time.
Digital Pathology Technology Landscape — key questions answered
Digital pathology covers the acquisition, management, analysis, and interpretation of pathology information in digital form. It now extends beyond slide digitization to encompass AI-driven biomarker prediction, genomic panel inference, spatial tumor microenvironment analysis, and real-time augmented reality (AR) microscopy.
Paige.AI, Inc. is the highest-volume assignee in this dataset, with at least 12 distinct records across US, CA, SG, AU, BR, JP, KR, WO, and CN jurisdictions. Genentech, Inc. / F. Hoffmann-La Roche AG collectively account for approximately 12–14 records covering spatial feature analysis, mutation prediction, heterogeneity assessment, and automated histologic sample assessment.
Rather than performing separate molecular assays, these systems train deep learning models to infer biomarker status (HER2, ER/PR), genomic panel elements, and actionable mutations directly from H&E or IHC-stained whole-slide images. The technical mechanism typically involves patch-level classification with a trained CNN or transformer followed by slide-level aggregation.
Spatial analysis of the tumor microenvironment focuses on quantifying the spatial relationships between different cell populations — notably tumor cells and lymphocytes — within tissue sections to generate immunophenotyping outputs, predict immunotherapy response, and stratify clinical trial eligibility. The mechanism involves detecting cell locations, computing spatial distribution metrics, and mapping these to predicted biological states.
Japan (JP) is the single most represented jurisdiction in this dataset with approximately 25 filings, predominantly international families filed by US-headquartered companies (Genentech/Roche, Paige.AI, Ventana/Roche, Janssen) entering the Japanese market. Korea (KR) follows with approximately 20 records.
Among the most recent filings (2024–2026), four directional signals are evident: self-supervised and foundation model architectures for histopathology (Janssen's DINOv2/simCLR approach); tumor heterogeneity quantification as a surrogate for molecular testing (Genentech); predictive biomarker discovery from standard-of-care H&E data (Insitro); and telepathology network intelligence for routing WSIs across distributed pathologist networks (QTC Management). A fifth signal is multimodal pathology integration combining histopathology with microbiome data, genomic sequencing, and liquid biopsy.
Still have questions? Let PatSnap Eureka answer them for you.
Search Digital Pathology Patents on EurekaMap Every Digital Pathology Patent Before Your Competitors Do
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D and identify IP whitespace across oncology, AI diagnostics, and computational pathology.
References
- Digital Pathology System and Associated Workflow for Providing Visualized Whole-Slide Image Analysis — Ventana Medical Systems, Inc., 2019, JP
- Digital Pathology System and Associated Workflow for Providing Visualized Whole-Slide Image Analysis — Ventana Medical Systems, Inc., 2020, JP
- Image-Based Risk Score — Prognostic Estimation of Survival and Outcomes from Digital Histopathology — New Jersey Medical School, 2012, CN
- Systems and Methods for Delivery of Digital Biomarkers and Genomic Panels — Paige.AI, Inc., 2021, US
- Systems and Methods for Delivery of Digital Biomarkers and Genomic Panels — Paige.AI, Inc., 2022, SG
- Systems and Methods for Delivery of Digital Biomarkers and Genomic Panels — Paige.AI, Inc., 2022, US
- Systems and Methods for Digital Biomarker and Genomic Panel Communication — Paige.AI, Inc., 2023, JP
- Systems and Methods for Digital Biomarker and Genomic Panel Communication — Paige.AI, Inc., 2025, JP
- Pathology Prediction Based on Spatial Feature Analysis — Genentech, Inc., 2023, JP
- Spatial Feature Analysis of Digital Pathology Images — Genentech, Inc., 2025, JP
- Tumor Immunophenotyping Based on Spatial Distribution Analysis — Genentech, Inc., 2024, JP
- Assessing Feature Heterogeneity in Digital Pathology Images Using Machine Learning Techniques — Genentech, Inc., 2026, JP
- Automated Digital Assessment of Histologic Samples — Genentech, Inc., 2023, WO
- Predicting Actionable Mutations from Digital Pathology Images — F. Hoffmann-La Roche AG, 2024, JP
- Artificial Intelligence Architecture for Predicting Cancer Biomarkers — The Regents of the University of California, 2024, BR
- Augmented Reality Microscope for Pathology with Overlay of Quantitative Biomarker Data — Google LLC, 2022, EP
- Pathologic Microscope, Display Module, Control Method and Apparatus, and Storage Medium — Tencent Technology (Shenzhen) Company Limited, 2024, US
- Active Learning System for Digital Pathology — Ventana Medical Systems, Inc., 2024, JP
- Attention-Based Learning for Digital Histopathology Analysis — Janssen Research & Development, LLC, 2026, JP
- System and Method to Optimize Telepathology Image Analysis — QTC Management, Inc., 2026, US
- Methods and Systems for Processing Pathology Data of a Patient for Pre-Screening Veterinary Pathology Samples — IDEXX Laboratories, Inc., 2024, WO
- Screening of Normal Endoscopic Large Bowel Biopsies with Artificial Intelligence — Wirral University Teaching Hospital, 2022 (6,591 WSIs, 3,291 patients)
- System and Method for Directly Predicting Survival of Cancer Patients Based on Histopathological Images — Verily Life Sciences LLC, 2024, JP
- Predicting Patient Outcomes Related to Pancreatic Cancer — Valar Labs, Inc., 2024, TW
- Systems and Methods for Processing Digital Images for Radiation Therapy — Paige.AI, Inc., 2022, US
- World Health Organization (WHO) — AI in Medical Imaging Guidance
- U.S. Food and Drug Administration (FDA) — Digital Pathology and AI/ML-Based Software as a Medical Device
- NHS — Artificial Intelligence in Pathology (UK National Health Service)
- European Patent Office (EPO) — AI Patent Trends in Medical Imaging
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This landscape is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.